Cerus Annual Report 2006

Plain-text annual report

COMMITTED TO PATIENTS, SCIENCE, SUCCESS COMMITTED TO PATIENTS, SCIENCE, SUCCESS Cerus 2006 Annual Report Cerus Corporation 2411 Stanwell Drive, Concord, California 94520 925.288.6000 T 925.288.6001 F www.cerus.com Product Pipeline Discovery Preclinical Phase I Phase II Phase III Marketing US US EU EU BLOOD SAFETY INTERCEPT Platelets INTERCEPT Plasma INTERCEPT Red Cells IMMUNOTHERAPY Cancer Therapy CRS-100 CRS-207 MEDI 543 (EphA2) Research Infectious Disease Anthrax Tularemia Research Executive Management and Board of Directors Executive Management Claes Glassell President and Chief Executive Ofﬁ cer William M. Greenman President, Cerus Europe David N. Cook, Ph.D. Senior Vice President, Research and Development Laurence M. Corash, M.D. Vice President and Chief Medical Ofﬁ cer William J. Dawson Vice President, Finance and Chief Financial Ofﬁ cer Thomas W. Dubensky, Ph.D. Vice President, Vaccine Research Howard G. Ervin Vice President, Legal Affairs Lori L. Roll Vice President, Administration and Corporate Secretary Board of Directors B.J. Cassin Chairman of the Board, Private Venture Capitalist Timothy B. Anderson Former Senior Vice President, Baxter International Inc. Laurence M. Corash, M.D. Vice President and Chief Medical Ofﬁ cer Bruce C. Cozadd Executive Chairman, Jazz Pharmaceuticals, Inc. Claes Glassell President and Chief Executive Ofﬁ cer William R. Rohn Former Chief Operating Ofﬁ cer, Biogen Idec Inc. s t t e s u h c a s s a M , n o t s o B , e v i t a e r C e a r e u l B : n g i s e D Corporate Information Forward looking Statement Statements in this annual report regarding future clinical trials, future regulatory ﬁ lings, potential efﬁ cacy of products, potential collaborations, future product development and commercial potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements as a result of certain factors, including the risks and uncer- tainty of the timing and results of clinical trials and other development activities, actions by regulatory authorities at any stage of the development process, additional ﬁ nancing activities, performance by partners, manufacturing, market acceptance of any products, competitive conditions, legal proceedings and other factors discussed in the company’s most recent ﬁ lings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this annual report. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise. Cerus, Helinx, INTERCEPT and INTERCEPT Blood System are trademarks of Cerus. Corporate Headquarters 2411 Stanwell Drive Concord, California 94520 Telephone: (925) 288-6000 Fax: (925) 288-6001 www.cerus.com Cerus Europe BV Kastanjelaan 1 3833 AN Leusden Telephone: 31 33 496060 Fax: 31 33 4960606 Corporate Counsel Cooley Godward LLP San Francisco, California Patent Counsel Morrison & Foerster LLP Palo Alto, California Auditors Ernst & Young LLP Palo Alto, California Registrar and Transfer Agent Wells Fargo Bank, N.A. 161 North Concord South St. Paul, Minnesota 55075 Telephone: (800) 401-1957 Fax: (651) 450-4033 Annual Report on Form 10-K A copy of the company’s Annual Report on Form 10-K as ﬁ led with the Securities and Exchange Commission is available without charge on request to: Investor Relations Department Cerus Corporation 2411 Stanwell Drive Concord, California 94520 Telephone: (925) 288-6000 Stock Information Common stock, traded on the Nasdaq Stock Market under the symbol: CERS Annual Meeting of Stockholders 9:00 a.m. Monday, June 4th, 2007 Cerus Corporation 2411 Stanwell Drive Concord, California 94520 CERUS CONDUCTED HEMOVIGILANCE STUDIES IN ROUTINE USE FOR OVER 12,000 TRANSFUSIONS TO FURTHER ESTABLISH THE SAFETY PROFILE OF INTERCEPT PLATELETS. ADDITIONAL STUDIES HAVE BEEN CONDUCTED IN PEDIATRIC PATIENTS TO EXPAND THE EXPERIENCE OF EARLIER CLINICAL TRIALS. TO DATE, MORE THAN 60,000 DOSES OF PLATELETS HAVE BEEN PREPARED AND TRANSFUSED IN OVER 40 BLOOD CENTERS IN 13 EUROPEAN COUNTRIES. COMMITTED Patients. Science. Success. These are what matter most to every member of the Cerus team. We believe that the promise of our science can best be realized by innovating novel products that may transform patient care. We focus the power of our science through the lens of patient need in order to identify products with clear medical and market potential. We have two marketed products in Europe to enhance blood safety, and our product development programs focus on improving the treatment of cancer and infectious diseases. We are committed to building science that is meaningful to patients, physicians and the healthcare system. 1 “At Cerus, we are committed to patients, science and success. Our achievements throughout this past year demonstrate our dedication to utilizing our technologies to create innovative products that address critical and unmet medical needs. We are committed to translating our technologies in the ﬁ elds of blood safety and immunotherapy into opportunities for success – for patients, healthcare providers and payors, our investors and our company.” – Claes Glassell, President & CEO, Cerus Corporation TO OUR STOCKHOLDERS: For Cerus, 2006 was a transformational year. We began the year by gaining rights to our INTERCEPT Blood System from Baxter International Inc. We then delivered on key initiatives throughout the year, particularly in our blood safety business. As a result of receiving European CE mark approval for the INTERCEPT plasma system in November 2006, we ended the year with two marketed products in Europe. We also fully enrolled patients in a Phase I clinical trial for our INTERCEPT red blood cell system in the United States, and established a European organization to support our sales and marketing initiatives. Our lead immunotherapy product candidate entered a Phase I clinical trial, and we have since received two separate research grants based on the promising technology platform that is the foundation for this program. The attainment of these many milestones conﬁ rms our dedication to our many constituents. COMMERCIAL PROGRESS Our momentum in 2006 was set in motion early in the year by gaining rights to develop and market the INTERCEPT Blood System from Baxter International Inc. The ability to market the INTERCEPT system under the Cerus brand is an important step in our evolution as a commercial organization. We intensiﬁ ed our presence in the European Union market by establishing a European subsidiary based in the Netherlands and hiring an experienced sales force throughout Europe, whose sole focus is to promote the INTERCEPT system. Our European presence has allowed Cerus to work closely with blood safety experts in key markets, leveraging the clinical and technical expertise of our sales force and scientiﬁ c support. Our sales force also has been introducing blood centers to the beneﬁ ts of the INTERCEPT Blood System. We believe that, as a paradigm shift away from testing, INTERCEPT will lead to signiﬁ cant improvement in European blood safety. Cerus’ marketing efforts were center stage at the September 2006 congress of the International Society of Blood Transfusion in Cape Town, South Africa. There, we promoted the INTERCEPT Blood System under the Cerus brand. Our technology was the subject of 20 scientiﬁ c abstracts, and Cerus hosted a standing-room-only symposium featuring notable world blood safety experts. Feedback received from congress attendees on the INTERCEPT Blood System was highly positive. Blood bankers told us that they value Cerus’ commitment to blood safety and appreciate the economic and logistic synergy between the INTERCEPT platelet and plasma systems. In November, Cerus received CE mark approval for the INTERCEPT Blood System for plasma. Receipt of this approval now allows Cerus to market the plasma system in many countries of the European Union. This regulatory approval was received in less than one year from our ﬁ ling date, demonstrating Cerus’ commitment to delivering on its stated goals in a timely manner. 2 Our momentum carried into 2007, as the French regulatory agency for medical products granted regulatory approval in January for use in France of plasma treated with the INTERCEPT system. Two weeks later, the Paul Ehrlich Institute, which regulates blood components in Germany, approved the marketing of platelets treated with the INTERCEPT system by a German blood center, the ﬁ rst approval anywhere in Germany. Our European sales team is on the way to establishing Cerus as the market leader for pathogen inactivation of blood components prior to transfusion. CLINICAL DEVELOPMENT We made progress in our clinical-stage blood safety and immunotherapy programs during 2006. We have fully enrolled patients in a U.S. Phase I clinical trial for the red blood cell system, which will evaluate the viability of red blood cells treated with the INTERCEPT system. The potential market opportunity in the United States, Europe and Asia for the red blood cell system is estimated to be in excess of $2.3 billion annually. We also initiated a Phase I clinical trial in the United States for our lead immunotherapy product candidate, CRS-100. This study is designed to determine the maximum tolerated dose and safety proﬁ le of a single dose of CRS-100 in adult patients with cancers that have metastasized to the liver. LOOKING TOWARD THE FUTURE Our commitment to patients, science and commercial success is unwavering. We will continue to focus on reaching key commercial, clinical and research goals, creating value-added catalysts for patients, the healthcare system and our shareholders. Charting new ground as the sole marketer of INTERCEPT in Europe, it was clear to us that we would need to raise additional capital to achieve our near-term goals. In 2006, we raised a total of $66.7 million in two separate stock offerings, broadening our institutional investor ownership and expanding our analyst coverage. We now have adequate capital to fund operations through 2008. Key priorities in the months ahead are to drive broader customer adoption for INTERCEPT products and to ensure that we can satisfy growing European customer demand for the INTERCEPT Blood System. We anticipate that the recent regulatory approvals in both France and Germany will lead to the signing of long-term contracts with regional blood centers in those countries, in turn accelerating broader European adoption of INTERCEPT. In our clinical stage programs, we expect to ﬁ le an Investigational New Drug Application for CRS-207, a therapeutic vaccine candidate for pancreatic, ovarian and non-small cell lung cancers, as well as mesothelioma, and subject to FDA concurrence, to initiate a Phase I clinical trial for CRS-207. We will continue working to maximize shareholder value by continuing to drive adoption of our commercial products and remaining a ﬁ nancially disciplined company. We are Cerus, delivering on our commitment to patients, science and success. Claes Glassell President & CEO Cerus Corporation April 27, 2007 3 “Bacterial contamination is the most signiﬁ cant infectious risk facing platelet transfusion recipients today. I believe patients will beneﬁ t from the higher level of protection offered by the INTERCEPT system, and I’m pleased that Lübeck can now supply INTERCEPT-treated platelets to our local hospitals.” – Dr. Peter Schlenke, Head of the Blood Donation Center of the Institute of Immunology and Transfusion Medicine, University of Lübeck School of Medicine THE INTERCEPT BLOOD SYSTEM The INTERCEPT Blood System is based on our Helinx technology, which cross-links nucleic acids (DNA and RNA) to prevent biological replication. When applied to blood components, the treatment targets pathogens such as viruses, bacteria and parasites, neutralizing their capacity to cause infection in transfusion recipients. White blood cells from the blood donor, which can cause harmful reactions in recipients, are also inactivated during the process. The three transfused components of blood – platelets, plasma and red blood cells – do not require DNA or RNA to function, so their therapeutic properties are not compromised. The INTERCEPT system is the only pathogen inactivation system licensed in Europe to treat both platelets and plasma units, delivering performance, ﬂ exibility and a higher level of process control for blood centers. The INTERCEPT platelet and plasma systems utilize the same illumination device, process and active compound in an open platform that is readily compatible with whole blood and apheresis collections. Over 60,000 INTERCEPT-treated platelet concentrates have been transfused to date, and the technology has been used clinically in over 40 blood centers located in 13 European countries. Plasma donations treated with the INTERCEPT system were evaluated in six clinical trials, with approximately 5,000 units transfused in all major indications for plasma transfusion. Signiﬁ cantly, the INTERCEPT platelet system provides a unique and compelling value proposition to blood centers and healthcare providers. The INTERCEPT platelet system replaces multiple other technologies currently used, such as bacterial detection, Cytomegalovirus testing and gamma irradiation. The system also provides important processing beneﬁ ts, allowing customers to optimize whole blood and apheresis collection. INTERCEPT-treated platelets may be stored for up to seven days, reducing the number of units discarded as a result of expiration. In routine use, blood centers (continued on page 9) 4 The Chikungunya Virus Epidemic in La Réunion How France’s national blood authority, EFS, acted quickly to protect the safety of platelets during an epidemic. Today, deadly viruses can move easily to Europe as travelers return from infected areas. Though some individuals will become ill, many more may experience few or no symptoms, and never recognize they have been infected. Also, these diseases are spread by migrating animals such as birds, or even mosquitoes trapped inside imported ﬂ owers and bamboo plants. PANDEMIC PREPAREDNESS IS ESSENTIAL TO PROTECT THE NATIONAL BLOOD SUPPLY Unfortunately, these new threats can be difﬁ cult to recognize when they ﬁ rst appear as there may be no existing tests, and infected blood may Even in countries with the most advanced blood systems, the blood slip into the blood supply. French blood donors must pass a detailed supply remains vulnerable to new infectious diseases. Each year brings medical history questionnaire and are then tested to ensure they are a new threat from diseases such as Avian ﬂ u, West Nile, Dengue Fever free of particular infections such as HIV and hepatitis. To achieve or the current Chikungunya virus crisis in the Indian subcontinent. an even higher level of safety, the EFS has evaluated a newer type of The Etablissement Français du Sang, or EFS, which is in charge of technology called pathogen inactivation, or PI. PI treatment can kill blood collection and preparation in France, must constantly monitor harmful organisms such as viruses and bacteria, similar in concept to the worldwide incidence of infections. During a pandemic of a blood- routine pasteurization of milk and other dairy products. When PI is in borne disease, when large numbers of people become infected at once, use, infectious threats can be neutralized even before infected donors are it is especially difﬁ cult to maintain the supply of safe blood products. identiﬁ ed. Recent experience in the overseas department of La Réunion during the Chikungunya virus epidemic demonstrates the difﬁ culties faced by local blood authorities during a national health emergency. CHIKUNGUNYA VIRUS EPIDEMIC IN LA RÉUNION: IMPACT ON THE LOCAL BLOOD SUPPLY In late 2005, the EFS faced an unexpected challenge to the national VIRUSES SPREAD ACROSS BORDERS QUICKLY blood supply when La Réunion became the epicenter of an explosive Today, deadly viruses can move easily to Europe as travelers return from regional outbreak of Chikungunya virus. Spread by the bite of infected infected areas. Though some individuals will become ill, many more may mosquitoes, the disease causes ﬂ u-like symptoms including severe experience few or no symptoms, and never recognize that they have been headache, fever, nausea, and joint pain. In fact, the curious name is infected. Also, these diseases are spread by migrating animals such as birds, Swahili for ‘that which bends up’ because of the stooped posture of or even mosquitoes trapped inside imported ﬂ owers and bamboo plants. victims suffering from sore joints. In contrast to earlier epidemics, in this outbreak the Chikungunya virus had undergone genetic changes and become more infectious and caused more serious disease such as bleeding, hepatitis, meningitis and fetal infection. The death rate from this infection was estimated to be 1 per 1,000 infected patients. By April 2006, this island in the Indian Ocean had an epidemic, with over The EFS made a rapid decision to implement INTERCEPT in La Réunion 250,000 infections out of a total population of approximately 750,000. to avoid critical shortages of platelets. Even though the process was not With one in three inhabitants already infected, and the remaining yet widely used in France, the process has been extensively studied by two-thirds at risk, EFS ofﬁ cials concluded that local blood donors were EFS Alsace under the direction of Prof. J.P. Cazenave, and personnel from not safe (i.e., free of Chikungunya virus) without signiﬁ cant changes Strasbourg traveled immediately to La Réunion to ensure that installation to standard blood collection and processing. Though implementation and training were successful. of new donor screening questions has often been used as a ﬁ rst line of response during epidemics, this simple precaution was not an option for La Réunion’s blood centers. Since then, the system has been used to treat over 1,500 units of platelets that otherwise might not have been available to the island hospitals. For two blood components, plasma and red blood cells, temporarily CHIKUNGUNYA VIRUS SPREADS TO EUROPE importing units from metropolitan France was the most practical Chikungunya cases have now been identiﬁ ed in six European countries, solution, but the third blood component, platelets, could not be including over 700 cases in France. These infections were diagnosed in imported because of the transportation time. travelers returning from the Indian Ocean, a popular tourist destination. Eurostat estimates that in 2004, over 1.4 million people traveled from MAKING LOCAL BLOOD SAFE: A NEW PI TECHNOLOGY FOR PLATELETS Madagascar, Mauritius, Mayotte, La Réunion and Seychelles to the The INTERCEPT Blood System is designed to inactivate most harmful European mainland. infections of emerging viruses such as West Nile and Dengue fever, as well as parasites that cause malaria and Chagas’ disease. In addition, the treatment also inactivates white blood cells and bacteria present in donated blood, which can be harmful to the blood recipient. With the recognition that infections were being imported came concern about the possibility of a local Chikungunya epidemic within Europe. The Asian tiger mosquito that spreads the disease, Aedes albopictus, has been found in a number of areas including the South of France and Corsica. “What we learned in La Réunion was that pathogen inactivation may be the only blood safety option to prevent transmission during an epidemic, and that we can implement a new system very easily and with little extra training. Since it started, the new INTERCEPT system has stood up to the rigors of daily use and their hospitals are operating with supplies of inactivated platelets, which are essential for their patients.” – Prof. J.P. Cazenave, a member of the Académie Nationale de Médecine At a March 2006 meeting in Stockholm, the European Centre for Disease “But pathogen inactivation is critical to blood safety at all times, not just Prevention and Control concluded that there is a risk for Chikungunya during an epidemic. We already use pathogen inactivation treatment for transmission in Europe, though the risk is difﬁ cult to determine and France’s plasma. However, for platelets and red blood cells, we currently would probably be limited to certain regions. The group of experts also rely on a range of other tests to detect a limited number of diseases. We stressed the need to broaden the risk assessment to vector-borne diseases can decide to add additional tests only when we know the problem. in general like West Nile and Dengue fever. However, we will never be able to test for all the things that might be A ROLE FOR PI IN ROUTINE BLOOD SAFETY European blood centers need a method that can kill harmful organisms in donated blood so that viruses and parasites can be prevented from infecting blood recipients. Since August 2006, EFS Alsace, under the in each blood donation. Pathogen inactivation treatment inactivates the widest spectrum of infections from viruses, parasites and bacteria.” INTERCEPT TREATMENT NOW AVAILABLE FOR BOTH PLASMA AND PLATELETS direction of Prof. Cazenave, a leading blood expert and member of the The INTERCEPT Blood System for plasma has recently received CE Académie Nationale de Médecine, has treated 100% of its platelet supply mark registration in Europe, and plasma treated with the INTERCEPT with the INTERCEPT system with no impact on daily operations or the system has received French regulatory approval. Therefore, INTERCEPT supply of platelets. In fact, treating physicians in the hospitals supplied is the ﬁ rst pathogen inactivation process that can be applied to both by EFS Alsace have observed a reduced number of acute transfusion platelets and plasma. reactions after using these treated platelets. Prof. Cazenave says: “We know that there is a risk for a pandemic to strike Europe, but we won’t know what infection, where or when until it is already happening. It might not be Chikungunya, but it could be Avian inﬂ uenza, it could be something else. We know our patients will continue to need transfusions. The challenge for blood centers is to plan for how we can continue to supply safe blood during a national health emergency like an epidemic.” COMMITTED TO PATIENTS AT CERUS, WE ARE COMMITTED TO HELPING PATIENTS LIVE BETTER LIVES THROUGH OUR SCIENTIFIC TECHNOLOGIES. have reported reductions in transfusion-related adverse events, indicating the INTERCEPT platelet system may help reduce hospitalization costs. Finally, the use of the INTERCEPT system may reduce the need to add additional tests as new pathogens emerge. The INTERCEPT plasma system also offers blood centers and healthcare payors a strong value proposition. The plasma system is priced competitively against other means of pathogen inactiva- tion for plasma and yet offers broader spectrum inactivation of pathogens and logistical advantages. These product attributes combine to make the INTERCEPT plasma system a superior solution for making transfused plasma units safer. Cerus initiated a Phase I clinical trial of the INTERCEPT red blood cell system in the United States during the third quarter of 2006. An estimated 35 million units of red blood cells are transfused in Europe, the U.S. and Japan each year to treat various indications ranging from severe trauma to genetic disorders. The INTERCEPT red blood cell system has been developed to inactivate blood-borne pathogens while leaving the therapeutic properties of red blood cells intact. At the congress of the International Society of Blood Transfusion, data from ongoing studies on the INTERCEPT system’s ability to inactivate pathogens in red blood cells using its modiﬁ ed S-303 treatment process were reported. Researchers found that the process effectively inactivates bacteria, including Staphylococcus aureus and Staphylococcus epidermidis, Yersinia enterocolitica, Escherichia coli and Serratia marcescens, as well as viruses such as HIV. We believe that the recent European regulatory approvals for the INTERCEPT system will support and expedite adoption of the INTERCEPT system for platelets and plasma in other countries. 9 COMMITTED TO SCIENCE OUR BLOOD SAFETY AND IMMUNOTHERAPY PLATFORMS ARE EACH BASED ON PROPRIETARY TECHNOLOGIES, REFLECTING OUR COMMITMENT T0 SCIENTIFIC DISCOVERY AND FOCUSED PRODUCT DEVELOPMENT. IMMUNOTHERAPY Cerus has several active immunotherapy product candidates that are based on our novel proprietary attenuated Listeria platform. Cancer cells are able to proliferate because the immune system fails to recognize them as foreign or abnormal, a condition known as immunologic tolerance. Our cancer immunotherapy candidates are designed to stimulate both innate and adaptive immune responses that may overcome this tolerance and enable the destruction of malignant cells. Many late-stage cancer vaccines have lacked the potency to break tolerance, and we believe that the potency of our Listeria platform provides the potential to be an advancement in cancer therapy. Our most advanced immunotherapy candidate is CRS-100. CRS-100 is a proprietary attenuated strain of the bacterium Listeria monocytogenes, an organism known to induce potent innate and adaptive immune responses. In the third quarter of 2006, we began enrolling patients in a clinical trial for CRS-100. This trial is designed to evaluate the safety and tolerability of CRS-100 in patients who have cancer that has metastasized to the liver and is refractory to standard treatment (or for whom no standard treatment is available). This study has experienced slower than expected patient enrollment. Working with the Institutional Review Boards at our clinical trial sites, we have modiﬁ ed the protocol so as to expand patient eligibility and accelerate dose escalation. We are also qualifying an additional clinical site to increase enrollment. 10 It is evident that the immune system can play a signiﬁ cant role in treating cancer. The challenge is to ﬁ nd safe and effective ways to generate potent immune responses that target cancer cells. Many late-stage cancer vaccines have lacked the potency to break immunologic tolerance, and we believe that the potency of our Listeria platform provides the potential to be an advancement in cancer therapy. We also made progress in the preclinical development of CRS-207, a therapeutic vaccine candidate for pancreatic, ovarian and non-small cell lung cancers, as well as mesothelioma. CRS-207 is being developed using the same proprietary strain of attenuated Listeria used in CRS-100, but in this product candidate the strain is engineered to express mesothelin, a protein found with high prevalence in pancreatic, ovarian and non-small cell lung cancers. Cerus conducted a multi-dose toxicology study in non-human primates that showed the ability of CRS-207 to break tolerance to mesothelin. 11 COMMITTED TO SUCCESS BY PIONEERING OUR TECHNOLOGIES, THE SUCCESSES ACHIEVED THIS PAST YEAR ACROSS OUR COMMERCIAL AND CLINICAL DEVELOPMENT PROGRAMS REFLECT OUR COMMITMENT TO SUCCESS AS A COMPANY. COMMITTED TO PATIENTS, SCIENCE AND SUCCESS In 2006, Cerus delivered on major milestones. We have already met two of our milestones for 2007: receipt of French national approval and the ﬁ rst receipt by a blood center in Germany of approval to sell INTERCEPT-treated platelets. To be committed is to be bound to a particular cause or course of action. Our cause is to improve the care of patients with serious medical conditions. Our course of action is to translate innovative science into products that address unmet medical needs. We thank you for your support and look forward to sharing our success with you in the months ahead. 12 Product Pipeline Discovery Preclinical Phase I Phase II Phase III Marketing US US EU EU BLOOD SAFETY INTERCEPT Platelets INTERCEPT Plasma INTERCEPT Red Cells IMMUNOTHERAPY Cancer Therapy CRS-100 CRS-207 MEDI 543 (EphA2) Research Infectious Disease Anthrax Tularemia Research Executive Management and Board of Directors Executive Management Claes Glassell President and Chief Executive Ofﬁ cer William M. Greenman President, Cerus Europe David N. Cook, Ph.D. Senior Vice President, Research and Development Laurence M. Corash, M.D. Vice President and Chief Medical Ofﬁ cer William J. Dawson Vice President, Finance and Chief Financial Ofﬁ cer Thomas W. Dubensky, Ph.D. Vice President, Vaccine Research Howard G. Ervin Vice President, Legal Affairs Lori L. Roll Vice President, Administration and Corporate Secretary Board of Directors B.J. Cassin Chairman of the Board, Private Venture Capitalist Timothy B. Anderson Former Senior Vice President, Baxter International Inc. Laurence M. Corash, M.D. Vice President and Chief Medical Ofﬁ cer Bruce C. Cozadd Executive Chairman, Jazz Pharmaceuticals, Inc. Claes Glassell President and Chief Executive Ofﬁ cer William R. Rohn Former Chief Operating Ofﬁ cer, Biogen Idec Inc. s t t e s u h c a s s a M , n o t s o B , e v i t a e r C e a r e u l B : n g i s e D Corporate Information Forward looking Statement Statements in this annual report regarding future clinical trials, future regulatory ﬁ lings, potential efﬁ cacy of products, potential collaborations, future product development and commercial potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements as a result of certain factors, including the risks and uncer- tainty of the timing and results of clinical trials and other development activities, actions by regulatory authorities at any stage of the development process, additional ﬁ nancing activities, performance by partners, manufacturing, market acceptance of any products, competitive conditions, legal proceedings and other factors discussed in the company’s most recent ﬁ lings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this annual report. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise. Cerus, Helinx, INTERCEPT and INTERCEPT Blood System are trademarks of Cerus. Corporate Headquarters 2411 Stanwell Drive Concord, California 94520 Telephone: (925) 288-6000 Fax: (925) 288-6001 www.cerus.com Cerus Europe BV Kastanjelaan 1 3833 AN Leusden Telephone: 31 33 496060 Fax: 31 33 4960606 Corporate Counsel Cooley Godward LLP San Francisco, California Patent Counsel Morrison & Foerster LLP Palo Alto, California Auditors Ernst & Young LLP Palo Alto, California Registrar and Transfer Agent Wells Fargo Bank, N.A. 161 North Concord South St. Paul, Minnesota 55075 Telephone: (800) 401-1957 Fax: (651) 450-4033 Annual Report on Form 10-K A copy of the company’s Annual Report on Form 10-K as ﬁ led with the Securities and Exchange Commission is available without charge on request to: Investor Relations Department Cerus Corporation 2411 Stanwell Drive Concord, California 94520 Telephone: (925) 288-6000 Stock Information Common stock, traded on the Nasdaq Stock Market under the symbol: CERS Annual Meeting of Stockholders 9:00 a.m. Monday, June 4th, 2007 Cerus Corporation 2411 Stanwell Drive Concord, California 94520 COMMITTED TO PATIENTS, SCIENCE, SUCCESS COMMITTED TO PATIENTS, SCIENCE, SUCCESS Cerus 2006 Annual Report Cerus Corporation 2411 Stanwell Drive, Concord, California 94520 925.288.6000 T 925.288.6001 F www.cerus.com

Continue reading text version or see original annual report in PDF format above